Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid

Annals of Pharmacotherapy

Volumn 41, Issue 10, 2007, Pages 1604-1610

  Gürcan, Hakan M ^a   Ahmed, A Razzaque ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Intravenous immunoglobulin; Pemphigoid; Pemphigus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; DIPHENHYDRAMINE; IBUPROFEN; IMMUNOGLOBULIN; LORAZEPAM; METHYLPREDNISOLONE SODIUM SUCCINATE; PARACETAMOL; PROCHLORPERAZINE MALEATE;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BRONCHOSPASM; BULLOUS PEMPHIGOID; CERVICAL LYMPHADENOPATHY; CHILL; DEATH; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HOARSENESS; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INCIDENCE; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PEMPHIGOID; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIGOR; SIDE EFFECT; STROKE; SWELLING; TACHYCARDIA; THORAX PAIN; URTICARIA; VOCAL CORD DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FATIGUE; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; PEMPHIGUS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 34748837776     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K198     Document Type: Article

References (38)

1. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 suppl):S525-53.
2. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9.
3. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84.
4. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol 2006;142:213-7.
5. Yockey SM, Ahmed I. Intravenous immunoglobulin-induced lichenoid dermatitis: a unique adverse reaction. Mayo Clin Proc 1997;72:1151-2.
6. Barbaud A, Trechot P, Granel F, et al. A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis. Dermatology 1999;199:258-60.
7. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004;38:2059-67. Epub 9 Nov 2004. DOI 10.1345/aph.1E040
8. Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy 2005;25: 886-92.
9. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6:535-42. Epub 13 Dec 2005.
10. Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999;48:518-21.
11. Gras V, Andrejak M, Decocq G. Acute renal failure associated with intravenous immunoglobulins. Pharmacoepidemiol Drug Saf 1999;8(suppl 1):S73-8.
12. Shah S, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm 2005; 62:720-5.
13. Center for Biologies Evaluation and Research. Important drug warning. www.fda.gov/medwatch/safety/1998/igiv.htm (accessed 2007 Feb 15).
14. Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-7.
15. Al-Wahadneh AM, Khriesat IA, Kuda EH. Adverse reactions of intravenous immunoglobulin. Saudi Med J 2000;21:953-6.
16. Sherer Y, Levy Y, Langevitz P, et al. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001;62:133-7.
17. Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003;4:358-62.
18. Stangel M, Kiefer R, Perte M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders - a prospective study. J Neurol 2003;250:818-21.
19. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
20. Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997;130:281-3.
21. Balfour-Lynn IM, Mohan U, Bush A, Rosenthal M. Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children. Arch Dis Child 2004;89:315-9.
22. Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 1999;91:126-33.
23. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005;16:313-8.
24. Marie I, Maurey G, Herve F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature. Br J Dermatol 2006;155:714-21.
25. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005;14:802-8.
26. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662- 4.
27. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
28. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-4.
29. Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003;139:991-3.
30. Sheehan DJ, Lesher JL Jr. Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris. Cutis 2004;73:403-6.
31. Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006; 39:601-7.
32. The FDA Safety Information and Adverse Event Reporting Program. 2002 Safety alert-immune globulin intravenous (human) (IGIV). www.fda.gov/cber/ infosheets/igiv082702.htm (accessed 2007 Feb 15)
33. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314:560-4.
34. McCluskey DR, Boyd NA. Anaphylaxis with intravenous gammaglobulin. Lancet 1990;336:874.
35. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986;26:410-2.
36. Thomas MJ, Misbah SA, Chapel HM, Jones M, Ellington G, Newsom-Davis J. Hemolysis after high-dose intravenous Ig (letter). Blood 1993; 82:3789.
37. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIg. Transfusion 2001;41:264-8.
38. Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006;39:513-7.